A Phase 1/2 interventional study of Olfactory mucosa-derived mesenchymal stem cells in Tracheal Stenosis, Laryngeal Stenosis and Mesenchymal Stem Cells, sponsored by The Republican Research and Practical Center for Epidemiology and Microbiology. Completed at 2 sites in Belarus. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-06-07.
Sponsored by The Republican Research and Practical Center for Epidemiology and Microbiology · Phase 1/2, Interventional, and Treatment
The trial evaluates the safety and efficacy of the olfactory mucosa-derived mesenchymal stem cells based therapy for the patients with chronic laryngeal and tracheal stenosis
Trial evaluating the safety and efficacy of olfactory mucosa-derived mesenchymal stem cells based therapy for the patients with chronic laryngeal and tracheal stenosis.
Mesenchymal stem cells are obtained from tissue biopsy of olfactory mucosa using explant method. Biomass of autologous mesenchymal stem cells in 10% human albumin solution is injected submucosally around and over the tissue after removal of a granuloma tissue during surgical intervention.
42 studies on the registry are indexed under Tracheal Stenosis; 11 are open to participants now.
This study's planned enrollment of 12 is below the median of 22 across 24 interventional studies indexed under Tracheal Stenosis.
Browse Tracheal Stenosis studies →The Republican Research and Practical Center for Epidemiology and Microbiology is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients treated according to current clinical protocols plus autologous olfactory mucosa-derived mesenchymal stem cells
Biological: Olfactory mucosa-derived mesenchymal stem cells
Patients treated according to current clinical protocols
Olfactory mucosa-derived mesenchymal stem cells
Number of patients who didn't require the repeated surgical interventions
Time frame: 1 year
Tracheostomy decannulation
Removal of the tracheostomy tube after the treatment.
Time frame: 6 month
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Republican Research and Practical Center for Epidemiology and Microbiology